journal
MENU ▼
Read by QxMD icon Read
search

Neurology and Therapy

journal
https://www.readbyqxmd.com/read/29987534/a-review-of-dementia-with-lewy-bodies-impact-diagnostic-criteria-and-treatment
#1
REVIEW
Samuel D Capouch, Martin R Farlow, Jared R Brosch
Dementia with Lewy bodies is one of the most common causes of dementia. It is not as common as Alzheimer's disease; the general public's awareness of the disease is poor in comparison. Its effects on caregivers and patients alike are not well known to the general population. There are currently no FDA-approved medications specifically for the treatment of DLB. Many of the medications that are approved for Alzheimer's disease are widely used in the treatment of DLB with varying degrees of success. Treatment of DLB is life long and requires a dedicated team of physicians and caregivers to minimize the degree of morbidity and mortality experienced by the patients suffering from the disease as it progresses...
July 9, 2018: Neurology and Therapy
https://www.readbyqxmd.com/read/29956263/monitoring-progressive-multiple-sclerosis-with-novel-imaging-techniques
#2
REVIEW
Maria Petracca, Monica Margoni, Giulia Bommarito, Matilde Inglese
Imaging markers for monitoring disease progression in progressive multiple sclerosis (PMS) are scarce, thereby limiting the possibility to monitor disease evolution and to test effective treatments in clinical trials. Advanced imaging techniques that have the advantage of metrics with increased sensitivity to short-term tissue changes and increased specificity to the structural abnormalities characteristic of PMS have recently been applied in clinical trials of PMS. In this review, we (1) provide an overview of the pathological features of PMS, (2) summarize the findings of research and clinical trials conducted in PMS which have applied conventional and advanced magnetic resonance imaging techniques and (3) discuss recent advancements and future perspectives in monitoring PMS with imaging techniques...
June 28, 2018: Neurology and Therapy
https://www.readbyqxmd.com/read/29923070/a-systematic-review-and-meta-analysis-of-the-brief-cognitive-assessment-for-multiple-sclerosis-bicams
#3
REVIEW
Freya Corfield, Dawn Langdon
Multiple sclerosis (MS) is a neurological disease of the central nervous system which can lead to a range of severe physical disabilities. A large proportion of those affected will experience cognitive impairment, which is associated with a worse prognosis. Effective assessment of cognition in MS has been problematic due to a lack of suitable scales. The Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) was developed in 2010 as part of an international endeavour to facilitate cognitive assessment...
June 19, 2018: Neurology and Therapy
https://www.readbyqxmd.com/read/29881979/only-follow-up-of-memory-b-cells-helps-monitor-rituximab-administration-to-patients-with-neuromyelitis-optica-spectrum-disorders
#4
Christine Lebrun, Mikael Cohen, Maria Alessandra Rosenthal-Allieri, Saskia Bresch, Sylvia Benzaken, Romain Marignier, Barbara Seitz-Polski, Michel Ticchioni
INTRODUCTION: Neuromyelitis optica spectrum disorders (NMOSD) are identified as a spectrum of inflammatory demyelinating disorders involving the brain, spinal cord and optic nerves. These disorders require early diagnosis and highly active immunosuppressive treatment. Rituximab (RTX) has demonstrated efficacy in limiting relapse in NMOSD when using several administration schedules. We questioned if the CD19+ CD27+ memory B cell count was a more reliable marker to monitor RTX administration than the RTX plasma level and CD19+ B cell count...
June 7, 2018: Neurology and Therapy
https://www.readbyqxmd.com/read/29728891/5ht6-antagonists-in-the-treatment-of-alzheimer-s-dementia-current-progress
#5
REVIEW
Megan Andrews, Babak Tousi, Marwan N Sabbagh
Alzheimer's disease is an important condition with a considerable and unmet disease burden in large need of continued research and more treatment options. The 5HT6 antagonists are a new class of medications to be offered. Because they are pro-cholinergic, these medications are to be used as adjuncts to acetylcholinesterase inhibitors (such as donepezil), further increasing acetylcholine in the central nervous system (CNS). Early trials of the 5HT6 antagonists showed improvements in cognition and activities of daily living when used as adjuncts to current therapies for Alzheimer's dementia...
June 2018: Neurology and Therapy
https://www.readbyqxmd.com/read/29704098/author-s-response-to-the-letter-to-the-editor-regarding-practical-treatment-of-lewy-body-disease-in-the-clinic-patient-and-physician-perspectives
#6
LETTER
Elisabet Londos
No abstract text is available yet for this article.
June 2018: Neurology and Therapy
https://www.readbyqxmd.com/read/29704097/editorial-regarding-practical-treatment-of-lewy-body-disease-in-the-clinic-patient-and-physician-perspectives
#7
EDITORIAL
Thomas Müller
No abstract text is available yet for this article.
June 2018: Neurology and Therapy
https://www.readbyqxmd.com/read/29704096/letter-to-the-editor-regarding-practical-treatment-of-lewy-body-disease-in-the-clinic-patient-and-physician-perspectives
#8
LETTER
Maksymilian Aleksander Brzezicki, Matthew David Kobetić
No abstract text is available yet for this article.
June 2018: Neurology and Therapy
https://www.readbyqxmd.com/read/29633228/positive-effectiveness-of-tafamidis-in-delaying-disease-progression-in-transthyretin-familial-amyloid-polyneuropathy-up-to-2-years-an-analysis-from-the-transthyretin-amyloidosis-outcomes-survey-thaos
#9
Rajiv Mundayat, Michelle Stewart, Jose Alvir, Sarah Short, Moh-Lim Ong, Denis Keohane, Denise Rill, Marla B Sultan
INTRODUCTION: The effectiveness of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy (TTR-FAP) was evaluated using data from the Transthyretin Amyloidosis Outcomes Survey (THAOS) registry. METHODS: Subjects receiving tafamidis (n = 252) were compared with untreated subjects in a non-randomized, matched cohort analysis. Subjects were matched with up to four untreated controls by genetic mutation, region of birth, and mean treatment propensity score...
June 2018: Neurology and Therapy
https://www.readbyqxmd.com/read/29611130/understanding-the-disease-course-and-therapeutic-benefit-of-tafamidis-across-real-world-studies-of-hereditary-transthyretin-amyloidosis-with-polyneuropathy-a-proof-of-concept-for-integrative-data-analytic-approaches
#10
Daniel Serrano, Christopher B Atzinger, Marc F Botteman
INTRODUCTION: Hereditary transthyretin (TTR) amyloidosis with polyneuropathy (hATTR-PN) is a rare, autosomal dominant amyloidosis characterized primarily by progressive ascending sensorimotor neuropathy often associated with  autonomic involvement. hATTR-PN is caused by a mutation in the TTR gene leading to protein misfolding and amyloid accumulation in peripheral nerves and vital organs. The latest global prevalence estimates point to 10,000 cases worldwide, with an upper end of about 40,000...
June 2018: Neurology and Therapy
https://www.readbyqxmd.com/read/29542041/atx-ms-1467-induces-long-term-tolerance-to-myelin-basic-protein-in-dr2-%C3%A3-ob1-f1-mice-by-induction-of-il-10-secreting-itregs
#11
Adriano Luís Soares De Souza, Stefan Rudin, Rui Chang, Keith Mitchell, Timothy Crandall, Shuning Huang, Ji-Kyung Choi, Shinji L Okitsu, Danielle L Graham, Blake Tomkinson, Tammy Dellovade
INTRODUCTION: Antigen-specific immunotherapy could provide a targeted approach for the treatment of multiple sclerosis that removes the need for broad-acting immunomodulatory drugs. ATX-MS-1467 is a mixture of four peptides identified as the main immune-dominant disease-associated T-cell epitopes in myelin basic protein (MBP), an autoimmune target for activated autoreactive T cells in multiple sclerosis. Previous animal studies have shown that ATX-MS-1467 treatment prevented the worsening of signs of disease in experimental autoimmune encephalitis (EAE) in the humanized (DR2 × Ob1)F1 mouse in a dose-dependent fashion...
June 2018: Neurology and Therapy
https://www.readbyqxmd.com/read/29524109/correction-to-risk-of-adverse-outcomes-for-older-people-with-dementia-prescribed-antipsychotic-medication-a-population-based-e-cohort-study
#12
Michael Dennis, Laura Shine, Ann John, Amanda Marchant, Joanna McGregor, Ronan A Lyons, Sinead Brophy
This article was originally published under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0), but has now been made available under a Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/ ), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made...
June 2018: Neurology and Therapy
https://www.readbyqxmd.com/read/29383493/treatment-with-botulinum-toxin-for-refractory-fever-caused-by-severe-spasticity-a-case-series
#13
Jacobo Lester, Gerardo Esteban Alvarez-Resendiz, Enrique Klériga, Fernando Videgaray, Gerardo Zambito
INTRODUCTION: Brain and spinal cord injuries may cause very severe spasticity that occasionally may be associated with persistent fever. CASE SERIES: We present 14 patients with spasticity and persistent fever, treated with botulinum toxin type A. Their spasticity improved and the fever resolved within a period no greater than 48 h. In all cases, infectious and other non-infectious causes were ruled out. CONCLUSIONS: When sustained tonic muscular activity is associated with a significant increase in body temperature and is refractory to the usual drugs used for hyperpyrexia, type A botulinum toxin may be an effective treatment option to control both spasticity and fever...
June 2018: Neurology and Therapy
https://www.readbyqxmd.com/read/29368093/parkinson-s-disease-the-dopaminergic-neuron-and-gammahydroxybutyrate
#14
Mortimer Mamelak
The high energy demands of the substantia nigra pars compacta dopaminergic (DASNc) neurons render these neurons vulnerable to degeneration. These energy demands are a function of their long and extensively arborized axons and very large number of transmitter release sites, and are further augmented by their natural pacemaking activity. Pacemaking is driven by the rhythmic entry of Ca2+ into the cell and, while the entry of Ca2+ into the neuron stimulates energy (ATP) production, the extrusion of Ca2+ conversely saps the energy that is generated...
June 2018: Neurology and Therapy
https://www.readbyqxmd.com/read/29260408/practical-treatment-of-lewy-body-disease-in-the-clinic-patient-and-physician-perspectives
#15
Elisabet Londos
This article describes the practical considerations in the clinical medical treatment in dementia with Lewy body (DLB) patients. It is illustrated with the voice of a DLB sufferer and his wife. According to our experience, emanating from a 15 year collaboration between a doctor and a nurse at a memory clinic, there are several possible therapeutical entrances. However, the order in which the medication is introduced is of great importance to avoid aggravation of other DLB symptoms. We start the treatment with cholinesterase inhibitor and memantine, and; thereafter, we treat the most disturbing symptom...
June 2018: Neurology and Therapy
https://www.readbyqxmd.com/read/29243029/vitamin-d-and-multiple-sclerosis-a-comprehensive-review
#16
REVIEW
Martina B Sintzel, Mark Rametta, Anthony T Reder
Numerous observational studies have suggested that there is a correlation between the level of serum vitamin D and MS risk and disease activity. To explore this hypothesis, a literature search of large, prospective, observation studies, epidemiological studies, and studies using new approaches such as Mendelian randomization was conducted. Available data and ongoing research included in this review suggest that the level of serum vitamin D affects the risk of developing MS and also modifies disease activity in MS patients...
June 2018: Neurology and Therapy
https://www.readbyqxmd.com/read/29243028/perspectives-from-the-patient-and-the-healthcare-professional-in-multiple-sclerosis-social-media-and-patient-education
#17
Daniel Kantor, Jeremy R Bright, Jeri Burtchell
A diagnosis of multiple sclerosis (MS) is life-altering. Because the course of MS is heterogeneous, patients may face uncertainty in terms of long-term physical and cognitive challenges, potential loss of employment, and the risk of social isolation. Patients often turn to the Internet and social media for information about MS and its management, and to seek out fellow patients and support groups. Here, we examine the use of social media and the Internet among patients with MS, considering its impact on patient education...
June 2018: Neurology and Therapy
https://www.readbyqxmd.com/read/29222700/perspectives-from-the-patient-and-the-healthcare-professional-in-multiple-sclerosis-social-media-and-participatory-medicine
#18
Daniel Kantor, Jeremy R Bright, Jeri Burtchell
When faced with a diagnosis of multiple sclerosis (MS), patients often turn to the Internet and social media to find support groups, read about the experiences of other people affected by MS and seek their advice, and research their condition and treatment options to discuss with their healthcare professionals (HCPs). Here, we examine the use of social media and the Internet among patients with MS, considering its impact on patient empowerment and patient participation in treatment decision-making and MS research...
June 2018: Neurology and Therapy
https://www.readbyqxmd.com/read/29177699/a-phase-ic-study-evaluating-the-safety-tolerability-pharmacokinetics-and-cognitive-outcomes-of-bi-409306-in-patients-with-mild-to-moderate-schizophrenia
#19
David Brown, Kristen Daniels, Solen Pichereau, Michael Sand
INTRODUCTION: This randomized, double-blind, parallel-group study investigated the safety, tolerability, pharmacokinetics (PK), and cognitive outcomes of BI 409306-a selective phosphodiesterase 9A (PDE9A) inhibitor-in patients with schizophrenia. METHODS: Patients with mild-to-moderate schizophrenia were randomized (1:1:1:1) to receive BI 409306 at 25, 50, or 100 mg or placebo once daily over 14 days. The primary endpoints were safety and tolerability; the secondary endpoints were PK and cognitive outcomes...
June 2018: Neurology and Therapy
https://www.readbyqxmd.com/read/29119538/safety-and-effectiveness-of-natalizumab-first-report-of-interim-results-of-post-marketing-surveillance-in-japan
#20
Takahiko Saida, Kazumasa Yokoyama, Ryusuke Sato, Haruki Makioka, Yukihiko Iizuka, Masakazu Hase, Yan Ling, Shinichi Torii
INTRODUCTION: Natalizumab, a humanized anti-α4 integrin monoclonal antibody, received marketing approval in Japan in 2014 for the treatment of multiple sclerosis (MS). Because the previous large-scale clinical trials of natalizumab were mainly conducted in Europe and North American countries, and data in patients with MS from Japan were limited, we conducted an all-case post-marketing surveillance of natalizumab-treated MS patients from Japan to investigate the safety and effectiveness of natalizumab in a real-world clinical setting in Japan...
December 2017: Neurology and Therapy
journal
journal
49896
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"